Watson Health is working hard to demonstrate the seriousness of its ongoing efforts in oncology, highlighting its research and customers at the recent American Society of Clinical Oncology (ASCO) conference. The Boston-based IBM business had six presentations at ASCO based on its data and touted that its oncology product is being used at more than 55 cancer centers globally.

Wide-neck bifurcations in cerebral aneurysms are among the most difficult to treat. Vancouver start up Evasc Neurovascular Enterprises ULC has developed the Eclips Aneurysm Remodeling System; it's expected to offer a potential new standard-of-care, particularly in wide-neck bifurcations. Better aneurysm option? The company has just secured a C$10 million ($7.5 million) series A financing that it expects will be sufficient to continue an ongoing European trial, to conduct a French trial aimed at reimbursement and to start an FDA IDE trial in early 2018. It also plans to update the current device with the funds,...

Wide-neck bifurcations in cerebral aneurysms are among the most difficult to treat. Vancouver start up Evasc Neurovascular Enterprises ULC has developed the Eclips Aneurysm Remodeling System; it's expected to offer a potential new standard-of-care, particularly in wide-neck bifurcations.

Orthopedics giant Stryker Corp. has long been committed to advancing 3-D printing in its manufacturing. It has completed a facility dedicated to 3-D manufacturing in Carrigtohill, County Cork, Ireland, and is now in the midst of filling it with the latest equipment. As part of this effort, the Kalamazoo, Mich.-based company now has partnered with GE Additive, which focuses on additive manufacturing that encompasses 3-D printing. The deal includes the provision of new additive machines, materials and services for use throughout Stryker's global supply chain operations. Stryker has a history of major buy-in for potentially...

Orthopedics giant Stryker Corp. has long been committed to advancing 3-D printing in its manufacturing. It has completed a facility dedicated to 3-D manufacturing in Carrigtohill, County Cork, Ireland, and is now in the midst of filling it with the latest equipment.

Centogene AG already has revenues from patient use of its expansive genetic testing portfolio for orphan disease patients – as well as from biopharma partnerships including a deal with rare disease specialist Shire plc. Now, the Rostock, Germany-based start up has secured a €25 million (US$28 million) series A round to expand its presence globally, broaden its biomarker as well as companion and genetic diagnostic offerings, as well as to move into oncogenetics. It aims to further build upon three business segments: Genetic Testing, Pharmaceutical Collaborations and Big Data Solutions. The former has been driving...

Centogene AG already has revenues from patient use of its expansive genetic testing portfolio for orphan disease patients – as well as from biopharma partnerships including a deal with rare disease specialist Shire plc. Now, the Rostock, Germany-based start up has secured a €25 million (US$28 million) series A round to expand its presence globally, broaden its biomarker as well as companion and genetic diagnostic offerings, as well as to move into oncogenetics.

Early cancer detection company Grail Inc. will merge with Hong Kong-based competitor Cirina Ltd. in an effort to boost its scientific efforts, as well as to better serve Asian markets. Financial details were undisclosed. Cirina was founded in 2014 by Dennis Lo, the first scientist to discover the presence of fetal DNA in the plasma of the pregnant mother, and Decheng Capital.

Early cancer detection company Grail Inc. will merge with Hong Kong-based competitor Cirina Ltd. in an effort to boost its scientific efforts, as well as to better serve Asian markets. Financial details were undisclosed.